<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have previously demonstrated that two prognostic features of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), mutant NRAS and over-expressing BCL-2, cooperate physically and functionally in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>Screening of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patient bone marrow (BM) identified NRAS:BCL-2 co-localization in 64% cases, correlating with percentage BM blasts, apoptotic features and disease status (p&lt;0.0001) </plain></SENT>
<SENT sid="2" pm="."><plain>Localization of the complex at the plasma membrane or the mitochondria correlated with disease and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> features in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, whilst caspase-9 mediated mechanism was elucidated in vivo and in vitro </plain></SENT>
<SENT sid="3" pm="."><plain>The intensity and localization of the <z:mp ids='MP_0011356'>RAS</z:mp>:BCL-2 complex merits further evaluation as a novel biomarker of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>